A citation-based method for searching scientific literature

Naosuke Nonoguchi, Takashi Ohta, Ji-Eun Oh, Young-Ho Kim, Paul Kleihues, Hiroko Ohgaki. Acta Neuropathol 2013
Times Cited: 144







List of co-cited articles
936 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
841
64

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
925
45

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
42

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Hideyuki Arita, Yoshitaka Narita, Shintaro Fukushima, Kensuke Tateishi, Yuko Matsushita, Akihiko Yoshida, Yasuji Miyakita, Makoto Ohno, V Peter Collins, Nobutaka Kawahara,[...]. Acta Neuropathol 2013
219
40

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
39

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
35

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Marianne Labussière, Blandine Boisselier, Karima Mokhtari, Anna-Luisa Di Stefano, Anais Rahimian, Marta Rossetto, Pietro Ciccarino, Olivier Saulnier, Rosina Paterra, Yannick Marie,[...]. Neurology 2014
123
29

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Christian Koelsche, Felix Sahm, David Capper, David Reuss, Dominik Sturm, David T W Jones, Marcel Kool, Paul A Northcott, Benedikt Wiestler, Katja Böhmer,[...]. Acta Neuropathol 2013
185
29

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
29

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
102
27

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
505
26

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Patrick J Killela, Christopher J Pirozzi, Patrick Healy, Zachary J Reitman, Eric Lipp, B Ahmed Rasheed, Rui Yang, Bill H Diplas, Zhaohui Wang, Paula K Greer,[...]. Oncotarget 2014
159
25

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
25

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
23

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
23

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
M Labussière, A L Di Stefano, V Gleize, B Boisselier, M Giry, S Mangesius, A Bruno, R Paterra, Y Marie, A Rahimian,[...]. Br J Cancer 2014
101
23

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
21

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Sabine Spiegl-Kreinecker, Daniela Lötsch, Bahil Ghanim, Christine Pirker, Thomas Mohr, Magdalena Laaber, Serge Weis, Alfred Olschowski, Gerald Webersinke, Josef Pichler,[...]. Neuro Oncol 2015
69
30

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
20

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
891
20

TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mohamed Ali Mosrati, Annika Malmström, Malgorzata Lysiak, Adam Krysztofiak, Martin Hallbeck, Peter Milos, Anna-Lotta Hallbeck, Charlotte Bratthäll, Michael Strandéus, Marie Stenmark-Askmalm,[...]. Oncotarget 2015
62
30

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
19

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Robert J A Bell, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci,[...]. Science 2015
285
19

Specific association of human telomerase activity with immortal cells and cancer.
N W Kim, M A Piatyszek, K R Prowse, C B Harley, M D West, P L Ho, G M Coviello, W E Wright, S L Weinrich, J W Shay. Science 1994
17

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Barbara Heidenreich, P Sivaramakrishna Rachakonda, Ismail Hosen, Florian Volz, Kari Hemminki, Astrid Weyerbrock, Rajiv Kumar. Oncotarget 2015
54
29


Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.
Xiaoli Liu, Guojun Wu, Yuan Shan, Christian Hartmann, Andreas von Deimling, Mingzhao Xing. Cell Cycle 2013
95
15

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender,[...]. Cancer Cell 2012
14

Altered telomeres in tumors with ATRX and DAXX mutations.
Christopher M Heaphy, Roeland F de Wilde, Yuchen Jiao, Alison P Klein, Barish H Edil, Chanjuan Shi, Chetan Bettegowda, Fausto J Rodriguez, Charles G Eberhart, Sachidanand Hebbar,[...]. Science 2011
621
14

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
P Sivaramakrishna Rachakonda, Ismail Hosen, Petra J de Verdier, Mahdi Fallah, Barbara Heidenreich, Charlotta Ryk, N Peter Wiklund, Gunnar Steineck, Dirk Schadendorf, Kari Hemminki,[...]. Proc Natl Acad Sci U S A 2013
205
14

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Jean Charles Nault, Maxime Mallet, Camilla Pilati, Julien Calderaro, Paulette Bioulac-Sage, Christophe Laurent, Alexis Laurent, Daniel Cherqui, Charles Balabaud, Jessica Zucman-Rossi. Nat Commun 2013
359
14

Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Kunitoshi Chiba, Joshua Z Johnson, Jacob M Vogan, Tina Wagner, John M Boyle, Dirk Hockemeyer. Elife 2015
139
14

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
428
14


Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T W Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes,[...]. Nature 2012
13

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
13

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu,[...]. Acta Neuropathol Commun 2016
110
13

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Melike Pekmezci, Terri Rice, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Helen Hansen, Hugues Sicotte, Thomas M Kollmeyer, Lucie S McCoy, Gobinda Sarkar,[...]. Acta Neuropathol 2017
146
13

The definition of primary and secondary glioblastoma.
Hiroko Ohgaki, Paul Kleihues. Clin Cancer Res 2013
526
12

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
12

Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma.
Chul-Kee Park, Se-Hoon Lee, Ji Young Kim, Ja Eun Kim, Tae Min Kim, Soon-Tae Lee, Seung Hong Choi, Sung-Hye Park, Il Han Kim. Oncotarget 2014
36
33

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
296
12

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Sumit Borah, Linghe Xi, Arthur J Zaug, Natasha M Powell, Garrett M Dancik, Scott B Cohen, James C Costello, Dan Theodorescu, Thomas R Cech. Science 2015
186
12

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
244
12

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat,[...]. Cancer Cell 2010
11

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Aden Ka-Yin Chan, Yu Yao, Zhenyu Zhang, Nellie Yuk-Fei Chung, Joseph Shu-Ming Liu, Kay Ka-Wai Li, Zhifeng Shi, Danny Tat-Ming Chan, Wai Sang Poon, Liangfu Zhou,[...]. Mod Pathol 2015
71
15

TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas.
Hideyuki Arita, Yoshitaka Narita, Hirokazu Takami, Shintaro Fukushima, Yuko Matsushita, Akihiko Yoshida, Yasuji Miyakita, Makoto Ohno, Soichiro Shibui, Koichi Ichimura. Acta Neuropathol 2013
45
24

Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.
Satoru Kyo, Masahiro Takakura, Toshiyoshi Fujiwara, Masaki Inoue. Cancer Sci 2008
243
11

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
353
11

Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Dong-Sheng Huang, Zhaohui Wang, Xu-Jun He, Bill H Diplas, Rui Yang, Patrick J Killela, Qun Meng, Zai-Yuan Ye, Wei Wang, Xiao-Ting Jiang,[...]. Eur J Cancer 2015
95
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.